Respiratory Panel (9 targets)
Respiratory Panel (9 targets)

[Product Name]

9 Respiratory Tract Pathogen Nucleic Acid Test Kit (Fluorescent PCR-Chip Method)

Respiratory Panel (9 targets) CH-RP9-001

[Packing Specifications]

12 tests / box 

[Applicable Models]

Flex-Disc (Model: CH-0104) Fully Automated Nucleic Acid Analyzer

[Download Brochure]

Respiratory Panel (9 targets)Chenghui-Flex-Disc-9-Respiratory-Tract-Pathogen-Nucleic-Acid-Detection-Kit-Brochure.pdf


No Data

Testing Process

No Data

[Intended Use]

9 Respiratory Tract Pathogen Nucleic Acid Test Kit (Fluorescent PCR-Chip Method) is a Fluorescent PCR-Chip assay intended for the qualitative detection of nine pathogens in human throat swab samples, including:

  1. Influenza A virus, 

  2. Influenza B virus, 

  3. SARS-CoV-2, 

  4. Respiratory syncytial virus, 

  5. Rhinovirus, 

  6. Adenovirus, 

  7. Parainfluenza virus, 

  8. Mycoplasma pneumoniae,

  9. Bordetella pertussis.

Challenges


Acute respiratory tract infections are the most common reason for outpatient and emergency department visits globally, and a core diagnostic challenge for primary care clinics, community health centers and public health systems. Conventional diagnostic approaches face four core unmet needs:


Highly overlapping symptoms driving empiric treatment and inappropriate antibiotic use

Community-acquired respiratory infections caused by influenza, RSV, Mycoplasma pneumoniae, Bordetella pertussis and other pathogens present nearly identical early symptoms including fever, cough and sore throat. Routine blood tests and clinical evaluation cannot distinguish viral, atypical bacterial and bacterial etiologies. This leads to high rates of missed diagnosis for pathogens such as pertussis and Mycoplasma, widespread unnecessary antibiotic use, and delayed targeted intervention for high-risk groups such as children and the elderly.


Trade-off between speed and accuracy in conventional testing

Centralized laboratory PCR testing typically takes 1–3 days to return results, too slow to support real-time outpatient and emergency clinical decision-making. Rapid antigen tests, while fast, have relatively low sensitivity, especially for low viral load samples and non-viral pathogens such as Mycoplasma pneumoniae and Bordetella pertussis, resulting in high false-negative rates.


High deployment barriers limiting access to molecular testing in primary care

Traditional nucleic acid testing requires standardized PCR laboratories and certified technical personnel, conditions that are largely unavailable in community clinics, township health centers and remote primary care settings. This leaves grassroots patients without access to precise molecular diagnosis, forcing them to travel to tertiary hospitals for testing.


Poor scalability to match fluctuating sample volumes

Respiratory infection seasons bring sharp surges in testing demand in hospital outpatient and emergency departments, while daily sample volumes in primary care settings remain low. Traditional high-throughput PCR instruments face high idle costs during off-peak periods, while single-channel low-throughput devices cannot handle peak demand, lacking a flexible, scalable solution.


Core Benefits


The 9 Respiratory Tract Pathogen Nucleic Acid Test Kit, paired with the Flex-Disc fully automated nucleic acid analysis platform, directly addresses the above outpatient and primary care pain points:


Respiratory Panel (9 targets)One-stop 9-plex profiling for accurate etiological differentiation

A single run covers 9 high-prevalence respiratory pathogens, including viruses, atypical pathogens and bacteria, enabling clear differentiation of infection types in one test. It accurately identifies easily missed pathogens such as Mycoplasma pneumoniae and Bordetella pertussis, provides clear etiological evidence for clinical decision-making, reduces unnecessary antibiotic use, and guides targeted treatment to shorten disease course.


Results in around 40 minutes to support real-time outpatient clinical decisions

Total testing time is around 40 minutes, with only 1 minute of hands-on sample loading. Patients can receive full diagnostic reports on the same visit, eliminating the need for multiple return trips and external sample delivery. It supports rapid triage and targeted treatment in emergency and outpatient settings, greatly improving clinical efficiency.


Low-barrier POCT deployment to extend molecular testing to primary care

The fully automated closed system requires no standardized molecular laboratory or specialized technical staff, and can be operated after simple training. It can be deployed directly in community health centers, grassroots clinics, school infirmaries and remote medical sites, allowing patients to access high-precision nucleic acid testing locally and reducing referral burdens.


Flexible modular throughput to adapt to diverse scenario needs

Powered by the Flex-Disc platform, each independent testing module processes one sample at a time, with a single control terminal supporting wireless connection to up to 8 modules simultaneously. Facilities can scale module count according to actual sample volume: single-module setup meets daily primary care demand, while multi-module parallel operation handles peak-season outpatient surges and public health screening, balancing operational cost and testing capacity.


Core Product Advantages


Outpatient and primary care-aligned 9-plex pathogen panel

The panel covers 9 high-prevalence community-acquired respiratory pathogens: Influenza A virus, Influenza B virus, SARS-CoV-2, Respiratory syncytial virus, Rhinovirus, Adenovirus, Parainfluenza virus, Mycoplasma pneumoniae and Bordetella pertussis. It fully covers viral, atypical bacterial and common bacterial etiologies, matching the core diagnostic needs of outpatient, emergency and primary care settings with an optimal balance of comprehensiveness and cost-effectiveness.


Fully automated closed sample-to-result workflow

Leveraging proprietary centrifugal microfluidic technology, the kit integrates two gold-standard workflows — silica membrane-based nucleic acid extraction and multiplex real-time qPCR — within a single enclosed disposable cartridge. Only 1 minute of manual pipetting is required, with no professional molecular operation expertise needed, delivering true load-and-go detection.


Modular scalable throughput design for flexible deployment

Compatible with the Flex-Disc (Model: CH-0104) Fully Automated Nucleic Acid Analyzer, each testing module processes 1 sample per run with full results available in around 40 minutes. One main control terminal can connect wirelessly to up to 8 testing modules, supporting random access and parallel testing to flexibly match sample volumes from small primary clinics to hospital outpatient departments.

Respiratory Panel (9 targets)


Lyophilized reagents for room-temperature storage and transport

With our self-developed PCR reagent lyophilization process, pre-embedded lyophilized reagent beads in the microfluidic chip enable room-temperature storage and transportation, eliminating cold chain reliance. This greatly reduces storage and logistics costs for primary care facilities and remote sites, supporting large-scale public health deployment.


Zero cross-contamination closed cartridge system

Each sample is processed in an individual sealed disposable cartridge, with amplification products never exposed to the external environment. This design fundamentally eliminates aerosol cross-contamination, reduces on-site quality control requirements, and ensures stable, reliable results even in non-laboratory primary care settings.


CE-compliant with clinically validated sample compatibility

The assay is fully validated for human throat swab samples, the most widely used sampling type for outpatient respiratory infection testing. All 9 targets are CE-marked, meeting regulatory requirements for clinical diagnosis and public health screening across global primary care and hospital outpatient markets.